Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immix Biopharma Inc IMMX

Healthcare Biotechnology
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMMX)

Immix Biopharma on Track to Dose NXC-201 Patients in United States

GlobeNewswire 1 day ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

GlobeNewswire 4 days ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

GlobeNewswire March 20, 2024

Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

GlobeNewswire March 5, 2024

Immix Biopharma 12 Month Review Progress Update

GlobeNewswire February 21, 2024

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

GlobeNewswire February 8, 2024

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

GlobeNewswire February 7, 2024

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

GlobeNewswire February 5, 2024

Immix Biopharma Announces Proposed Public Offering of Common Stock

GlobeNewswire February 5, 2024
View More News ››

Opinion & Analysis (NDAQ:IMMX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMMX)

Immix Biopharma Announces Closing of $15 Million Public Offe

NEWS: $IMMX Immix Biopharma Announces Closing of $15 Million Public Offering of Common StockLOS ANGELES, CA, Feb. 08, 2024 (GLOBE...
whytestocks - February 8, 2024

Immix Biopharma Statement On January 2024 FDA Labeling Chang

News; $IMMX Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T ProductsLOS ANGELES, CA, Jan...
whytestocks - January 24, 2024

New coverage on IMMX!

https://youtu.be/616ReCUzJuA?si=vqEmN8RLDA309UM3
BryceCanada - December 6, 2023

How does great News

Turn into a drop in the SP.............WTF
silverT - May 3, 2023

Wow huge jump today!

https://youtu.be/JFSoXiLB2Ks
BryceCanada - December 14, 2022

IMMX....has done well this a.m....

I'd say its at resistance here at $2.40 Cheers !
Iseneschal - December 14, 2022
View more Bullboard ››

Blue Sky Uranium Corp

Blue Sky Uranium Corp

Blue Sky Uranium Corp. is a uranium and vanadium exploration company. The Company is focusing its uranium and vanadium ...
View More »